Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2021 5
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.
Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. Among authors: okuno t. J Geriatr Oncol. 2022 Jan;13(1):88-93. doi: 10.1016/j.jgo.2021.07.002. Epub 2021 Jul 6. J Geriatr Oncol. 2022. PMID: 34238726
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.
Kobayashi T, Ito K, Kojima T, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Ogawa O, Kitamura H, Nishiyama H. Kobayashi T, et al. Among authors: okuno t. Cancer Immunol Immunother. 2022 Feb;71(2):461-471. doi: 10.1007/s00262-021-03000-8. Epub 2021 Jul 7. Cancer Immunol Immunother. 2022. PMID: 34235546 Free PMC article.
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group. Kobayashi M, et al. BJU Int. 2022 Aug;130(2):226-234. doi: 10.1111/bju.15510. Epub 2021 Jul 6. BJU Int. 2022. PMID: 34110696
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Kato M, et al. Int J Urol. 2021 Dec;28(12):1261-1267. doi: 10.1111/iju.14686. Epub 2021 Sep 20. Int J Urol. 2021. PMID: 34545627
[Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma].
Fukunaga A, Yamasaki T, Okuno T, Imai K, Ikeuchi R, Hishiki K, Goto T, Sawada A, Negoro H, Akamatsu S, Saito R, Kobayashi T, Inoue T, Ogawa O. Fukunaga A, et al. Among authors: okuno t. Hinyokika Kiyo. 2018 Oct;64(10):383-389. doi: 10.14989/ActaUrolJap_64_10_383. Hinyokika Kiyo. 2018. PMID: 30543735 Free article. Japanese.